Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

You must log in to access content on this page. Or click here to request access.
Advancing fluorescent tracer agents and their transdermal detection.

The goal of MediBeacon’s fluorescent tracer agent-based systems is to provide clinically relevant information that can cost effectively and positively impact patient care.

Accurate physiological measurements made in real-time, are vital in the hospital as well as in the management of chronic diseases. Fluorescent tracer agent-based monitoring systems are being designed to provide an indication of GFR, quantification of GI permeability, enhanced visualization of the vasculature during ocular angiography, and identification of the ureters during abdominal surgeries.*

The goals in the development of fluorescent tracer agents for physiological monitoring are to:
  • Engineer molecules that do not interact with the body.
  • Optimize molecules so they may be optimally detected by transdermal sensors.

MediBeacon products are in various stages of clinical development and are not yet approved for human use.


The MediBeacon Transdermal GFR Measurement System (TGFR) is comprised of three distinct parts.

Lumitrace® (relmapirazin) is an investigational pyrazine-based compound which has been engineered to be inert, highly fluorescent and have the clearance properties of a GFR tracer agent in the body.

The TGFR Sensor contains a light source and photo detector for the noninvasive detection of the transdermal fluorescence from Lumitrace and is attached to one of several positions on the body using a biocompatible adhesive. The transdermal sensor has a built-in cable that connects to the monitor.

The TGFR Monitor provides power to the sensor, digitizes the data acquired from the sensor, contains the algorithms to run the sensor and converts the output to a tGFR which is displayed on the monitor.

The TGFR Monitor displays real-time information regarding the rate of decrease in Lumitrace fluorescence and how this changes over time. The monitoring of tGFR changes may prove clinically useful in the assessment of GFR at the point of care. The TGFR Monitor displays Snapshot GFR values during a TGFR monitoring session. Snapshot GFR values summarize fluorescence data collected by the TGFR Sensor and are intended to provide an indication of changes in tGFR over time. The duration of a transdermal GFR monitoring session depends on a patient’s kidney function. Watch the animation.

MediBeacon products are in various stages of clinical development and are not yet approved for human use.

MediBeacon products are in various stages of clinical development and are not yet approved for human use.


Orally administered fluorescent tracer agents
The oral administration of fluorescent tracer agents coupled with transdermal detection technology are being studied to see how the technology could enable a clinically practical measurement of gut permeability.


Patient administered fluorescent tracer agent-based systems The adaptation of fluorescent tracer agent-based systems for use in the outpatient and eventually, in-home setting are important initiatives.